Cybin’s depression program advancing in Phase 3, says H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $190 price target on Cybin (CYBN) shares, telling investors in a research note that top-line data from the company’s anxiety program is on track for the first quarter of 2025 and from its pivotal depression program in 2026. Cybin’s programs are overall advancing in-line with the firm’s expectations, and H.C. Wainwright says it is looking forward to the next updates to drive potential upside.